MUC1 is a gene that instructs for the production of Mucin protein. Mucin acts as a lubricant in the body cavities and airways that protects the inner linings of the airways, digestive tract, reproductive tract, and other organs. MUC1 inhibitors are a promising class of drugs designed to target MUC1, a transmembrane glycoprotein overexpressed in various cancers. MUC1 plays a crucial role in tumor progression and immune evasion, making it an attractive therapeutic target. These inhibitors act on the extracellular domain of MUC1, preventing its interaction with other receptors or molecules involved in tumor growth and metastasis. By inhibiting MUC1, these drugs aim to disrupt tumor cell signaling and enhance the immune response against cancer cells. MUC1 inhibitors show potential in treating a wide range of cancers, including breast cancer, pancreatic cancer, lung cancer, and ovarian cancer. In breast cancer, for example, MUC1 overexpression is associated with more aggressive tumor behaviour and poor prognosis. According to the World Health Organization (WHO), breast cancer is the most common cancer in women worldwide, with an estimated 2.3 million new cases diagnosed in 2020. This staggering statistic highlights the urgent need for effective therapies like MUC1 inhibitors to combat this devastating disease. As ongoing research delves deeper into the mechanisms and efficacy of MUC1 inhibitors, these novel agents hold tremendous promise in revolutionizing cancer treatment and improving patient outcomes in the future. Extensive research is being conducted to find new and novel molecules to prevent and cure diseases like Bronchial neoplasms. The development and launch of more unique products by the market players will significantly enhance the revenue of the MUC1 Inhibitor market over the forecast years.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. 21 companies in their pipelines have 104 products in various stages of clinical trials. 2 products are in Phase 3, 12 products are in Phase 2, and 4 products are in Phase 1 of the clinical trials.
Drugs in Pipeline
- ETBX-061
- Stimuvax (tecemotide)
- Panvac-VF (falimarev/inalimarev)
- MUC1 peptide-poly-ICLC adjuvant vaccine
- mesmulogene ancovacivec (TG4010)
- GO-203-2c
- ONT-10
- PankoMab-GEX (gatipotuzumab)
- BTH1704
- BrevaRex (AR20.5)
- HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, B7-H3 targeting CAR-TILs
- HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, B7-H3 targeting TILs
- ImMucin (VXL100)
- MUC-1 CD40L dendritic cell vaccine
- PDC*lung01
- Tri-Ad5
- activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody
- anti-MUC1 CAR-pNK cells
Clinical Activity and Developments of MUC1 Inhibitor
As of July 2023, 18 products for 86 diseases are in 17 clinical trials. For instance,
- Merck KGaA is conducting a Phase 3 clinical trial of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in Non-small Cell Lung Cancer (NSCLC) subjects with unresectable stage III disease to compare the survival duration of all randomized subjects by treatment arm.
- In February 2023, National Cancer Institute completed a Phase 2 clinical trial of combination immunotherapy in subjects with Advanced Small Bowel and Colorectal Cancers.
- National Cancer Institute is conducting a Phase 2 clinical trial of MUC1 Vaccine in patients with newly diagnosed Advanced Adenomas.
|
Molecule name |
Number of studies |
|
ETBX-061 |
20 |
|
Stimuvax (tecemotide) |
17 |
|
Panvac-VF (falimarev/inalimarev) |
13 |
|
MUC1 peptide-poly-ICLC adjuvant vaccine |
6 |
|
mesmulogene ancovacivec (TG4010) |
6 |
Target Indication Analysis of MUC1 Inhibitor
MUC1 inhibitors have emerged as potential therapeutic agents with diverse applications, particularly in cancer treatment. One of the primary indications for these inhibitors is breast cancer, where MUC1 is frequently overexpressed, contributing to tumor aggressiveness and metastasis. Additionally, MUC1 inhibitors show promise in combating pancreatic cancer, a notoriously challenging disease with limited treatment options—lung cancer, another aggressive malignancy, benefits from these inhibitors, targeting MUC1 overexpression for improved outcomes. Ovarian cancer, known for its high recurrence rates, is also an area where MUC1 inhibitors are being investigated. Furthermore, MUC1 inhibitors have shown potential in treating prostate cancer, a prevalent malignancy affecting males globally. Gastric cancer, characterized by MUC1 overexpression, is an additional indication under scrutiny for targeted therapy using MUC1 inhibitors. As research progresses, MUC1 inhibitors may find broader applications in various other cancers, fostering new avenues in precision medicine and providing hope for more effective treatments for cancer patients worldwide.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Currently, no MUC1 Inhibitors have been approved by the FDA
These are being evaluated for various indications like Breast cancer, Ovarian cancer, Bronchogenic carcinoma, Non-small Cell Lung Cancer, and others.
ImmunityBio, Ono Pharmaceutical, Bavarian Nordic, and the University of Pittsburgh are some of the major market players for MUC1 inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of disorders like Breast and Ovarian Cancer are the key opportunities for MUC1 inhibitors in the market.
- ImmunityBio
- Ono Pharmaceutical
- Bavarian Nordic
- University of Pittsburgh
- Transgene
- Genus Oncology
- Seagen Inc
- Glycotope GmbH
- HiberCell
- CanariaBio Inc
- Zhaotai InVivo Biomedicine
- Vaxil Biotherapeutics
- IMV Inc
- MicroVAX LLC
- PDC line Pharma
- Benhealth Biopharma
- PersonGen Biomedicine